Ed Gillen has spoken out about the moment a speck in his eye spiraled into total blindness, which he blames on Ozempic.
Gillen, 58, a former Massachusetts state highway worker from Dedham, told Boston 25 News that he woke up one Saturday morning in May of last year with what seemed like a minor irritation. He contacted his doctor and scheduled an appointment, assuming the issue would resolve quickly.
Instead, his vision deteriorated with terrifying speed. Within two weeks, the speck had become something far worse. As his daughter drove him to the hospital in a panic, his sight faded entirely before they even reached the emergency room.
“I need a wheelchair. I can’t walk,” Gillen recalled telling hospital staff when he arrived. When they asked why, he remembers replying simply: “I can’t see.”
Early CT scans came back clean, but a neuro-ophthalmologist ran extensive tests and delivered a devastating diagnosis. The specialist told him his sudden blindness was directly tied to the medication he had been taking to manage his blood sugar.
“I was taking Ozempic for my A1C,” Gillen confirmed.
The doctor, he recalled, ran him through exhaustive testing and concluded the symptoms were definitively linked to the GLP-1 drug. Gillen remembered the exchange: “Yeah this is definitely symptoms of taking the GLP 1 Ozempic’, and I said, ‘Okay what do we do now?'”
The answer was grim. There was no reversing the damage. Gillen was forced to abandon a 39-year career as a state highway worker and adjust to life with a permanent disability.
“So, I’m blind for the rest of my life, but I’m still me and I want to let people know you can still be you,” he added.
Now Gillen is pursuing legal action against the drug’s manufacturer while working to warn others about potential risks. His message centers on vigilance rather than blanket rejection of the medication.
“‘It’s not going to happen to me’ – don’t think like that because everybody’s at risk. Follow the risk factors. Know your body,” he warned.
He clarified that his goal is not to tell people to stop taking Ozempic, but to make sure they understand what could go wrong. “I want to also with this lawsuit be able to make people aware. Not necessarily tell them stop taking it. That’s on them. But just be aware.”
Novo Nordisk, the manufacturer of Ozempic, has pushed back hard against the allegations. The company issued a statement calling personal injury lawsuits filed in the U.S. “without merit” and said it is “vigorously defending them.”
The statement acknowledged awareness of reports and epidemiological data concerning non-arteritic anterior ischaemic optic neuropathy in patients treated with semaglutide, but noted that “a causal relationship between semaglutide and NAION has not been established.” The company emphasized that patient safety remains its top priority and that it collaborates closely with health authorities worldwide.
The condition that struck Gillen, NAION, is a rare form of optic nerve damage sometimes called an “eye stroke” that can cause sudden, painless vision loss. While research into potential links between GLP-1 drugs and this condition remains ongoing, Gillen’s case represents one of the growing number of patient reports fueling litigation against the popular weight-loss and diabetes medication makers.
Gillen’s ordeal began with that single speck on a Saturday morning and escalated to complete darkness before the month was out. The rapid progression left him no time to prepare for a life without sight, transforming a routine medication for blood sugar management into what he describes as a nightmare.
He continues to adapt to his new reality while pressing forward with his lawsuit, determined to turn his personal tragedy into a warning that might spare others similar harm.
Gillen is expected to continue his legal proceedings against Novo Nordisk in the coming months.